Ultra high resolution Single Photon Computed Emission Tomography for the molecular imaging of brain disease

Project Information

BRAINSPECT

Grant agreement ID: 673306

DOI

10.3030/673306

Project closed

EC signature date 20 April 2015

Start date 1 May 2015

End date 31 October 2015

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

Milabs BV
Netherlands

Periodic Reporting for period 1 - BRAINSPECT (Ultra high resolution Single Photon Computed Emission Tomography for the molecular imaging of brain disease)

Reporting period: 2015-05-01 to 2015-10-31

Summary of the context and overall objectives of the project

MILabs Molecular Imaging Laboratories BV has researched the marketing and commercial feasibility of G-SPECT as a highly improved imaging modality to reposition SPECT for the use in indications that are currently diagnosed with SPECT, that are currently diagnosed with another imaging modality, or that are under diagnosed in another way. G-SPECT is a molecular imaging device using highly sensitive technology to measure functional changes, in a faster manner or using lower tracer doses, by making use of a proprietary unprecedented collimation, reconstruction and acquisition technology and subsequent image extraction software. G-SPECT’s speed and resolution is far superior over current SPECT.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

This feasibility report comprises an inventory of relevant stakeholders and their willingness to support the market introduction of G-SPECT, the assessment of market opportunities and trends, a description of the unmet needs that currently exist in several disease areas, the opportunities and threats in the market, an analysis of IP and FTO and identification of regulatory and reimbursement demands in different geographical areas with the final aim to confirm the commercial feasibility of G-SPECT and to develop a sound business strategy around that. In addition, as part of BRAINSPECT Phase 1, we have optimised G-SPECT with the scanning of several phantoms to optimise the software for the clinical application of G-SPECT.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Based on the results of this study we have concluded that this product has and is receiving an enormous amount of interest from the field and that it is the opinion of many that G-SPECT can bring a significant contribution to the diagnostic standard of several indications in the fields of neurology, cardiology and oncology. The product has a high commercial viability and a great potential to disrupt the molecular imaging market within the next years. In addition we have created a sound business strategy for the current and future sales and marketing of

The very positive feedback as received from important stakeholders has further strengthened our believe that G-SPECT is a highly innovative and clinically relevant solution to improve treatment approaches by better stratifying patients and by improving the treatment decision making process.

milabs-g-spect-300-dpi.jpg